專家信息：

石智，男，暨南大學(xué)生命科學(xué)技術(shù)學(xué)院生物醫(yī)藥研究院教授，博士生導(dǎo)師。

主要從事腫瘤細(xì)胞生物學(xué)和藥理學(xué)工作，以第一和通訊作者（含共同）在Signal Transduct Target Ther、Cancer Res（4篇）、Oncogene、J Biol Chem、Br J Pharmacol、Cancer Lett （2篇）、Biotechnol Adv、Med Res Rev、Trends Cancer和Drug Discov Today（2篇）等期刊發(fā)表SCI論文56篇，總影響因子280點(diǎn)，Google學(xué)術(shù)中被Nat Rev Cancer、Nat Rev Drug Discov等期刊引用2496次，單篇最高320次，另以合作作者發(fā)表SCI論文28篇，H指數(shù)40，英文書籍章節(jié)3篇。獲授權(quán)美國(guó)專利1項(xiàng)、中國(guó)專利9項(xiàng)，申請(qǐng)中國(guó)專利2項(xiàng)，主持國(guó)家重點(diǎn)研發(fā)計(jì)劃子課題、國(guó)家自然科學(xué)基金、廣東省自然科學(xué)杰出青年基金和廣州市產(chǎn)學(xué)研協(xié)同創(chuàng)新重大專項(xiàng)等15項(xiàng)基金，入選廣東省特支計(jì)劃科技創(chuàng)新青年拔尖、廣東省千百十工程校級(jí)培養(yǎng)計(jì)劃和暨南大學(xué)杰出青年學(xué)者支持計(jì)劃，獲得中國(guó)抗癌協(xié)會(huì)科技獎(jiǎng)一等獎(jiǎng)、廣東省科學(xué)技術(shù)獎(jiǎng)一等獎(jiǎng)和中國(guó)藥理學(xué)會(huì)施維雅青年藥理學(xué)家獎(jiǎng)等獎(jiǎng)項(xiàng)12項(xiàng)，擔(dān)任國(guó)家自然科學(xué)基金、廣東省自然科學(xué)基金和廣東省科技獎(jiǎng)等評(píng)審專家，中國(guó)抗癌協(xié)會(huì)抗癌藥物專業(yè)委員會(huì)、中國(guó)藥理學(xué)會(huì)腫瘤藥理專業(yè)委員會(huì)和分子藥理專業(yè)委員會(huì)委員、廣東省藥理學(xué)會(huì)腫瘤藥理專業(yè)委員會(huì)候任主任委員和廣東省抗癌協(xié)會(huì)抗癌藥物專業(yè)委員會(huì)副主任委員，Mol Pharmacol和Recent Pat Anti-Cancer期刊編委，Mol Cancer等近100個(gè)SCI期刊審稿人。與美國(guó)Emory大學(xué)、St John’s大學(xué)和Tennessee大學(xué)等科研機(jī)構(gòu)開展科研合作。

學(xué)習(xí)及工作經(jīng)歷：

1997-2002，中山大學(xué)中山醫(yī)學(xué)院法醫(yī)學(xué) 學(xué)士。

2002-2007，中山大學(xué)腫瘤防治中心腫瘤學(xué) 博士。

2006-2007，美國(guó)St. John's大學(xué)藥學(xué)院 訪問學(xué)者。

2007-2011，美國(guó)Emory大學(xué)醫(yī)學(xué)院藥理系 博士后。

2012至今，暨南大學(xué)生命科學(xué)技術(shù)學(xué)院生物醫(yī)藥研究院/細(xì)胞生物系 研究員、博士生導(dǎo)師。

社會(huì)職務(wù)：

1. 學(xué)術(shù)團(tuán)體職務(wù)：

中國(guó)抗癌協(xié)會(huì)抗癌藥物專業(yè)委員會(huì)、中國(guó)藥理學(xué)會(huì)腫瘤藥理專業(yè)委員會(huì)和分子藥理專業(yè)委員會(huì)委員、廣東省藥理學(xué)會(huì)腫瘤藥理專業(yè)委員會(huì)候任主任委員和廣東省抗癌協(xié)會(huì)抗癌藥物專業(yè)委員會(huì)副主任委員。

2.  專業(yè)期刊編委

Mol Pharmacol和Rencent Pat Anti-Cancer

3.  專業(yè)期刊審稿人：

Acta Biochim Biophys Sin、Acta Pharm Sin B、Acta Pharmacol Sin、Aging、Amino Acids、Anticancer Agents Med Chem、Arch Biochem Biophys、Asian J Pharm Sci、BBA-Mol Basis Dis、Bioengineered、Biology、Biomed Pharmacother、Biomolecules、Biomed Res Int、BMC Cancer、BMC Pharmacol Toxicol、Cancers、Cancer Biother Radiopharm、Cancer Lett、Cancer Manag Res、Cell Biol Int、Cell Commun Signal、Cell Proliferat、Cheml Bio Drug Des、Chin J Cancer/CancerCommun、Clin Exp Pharmacol P、Comput Struct Biotechnol J、Curr Pharm Biotechnol、Diseases、Drug Deliv、Drug Des Dev Ther、Epigenomics、Expert Opin Drug Del、Exp Ther Med、Eur J Pharmacol、Food Chem Toxicol、Food Funct、Front Cell Dev Biol、Front Endocrin、Front Mol Biosci、Front Med、Front Microbiol、Front Oncol、Front Pharmacol、Front Toxicol、Future Oncol、Heliyon、Int J Biol Sci、Int J Clin Pract、Int J Mol Sci、Int J Mol Med、Int J Oncol、Int J Pharm、Integr Cancer Ther、IUBMB Life、 J Cancer、J Cell Mol Med、J Funct Foods、 J Interg Med、J Inflamm Res、J Mater Chem B、J Mol Cell Biol、J Nutr Biochem、J Pharmcol Exp Ther、J Pharm Pharmcol、J Phys Chem、Life Sci、Med Sci Monit、Molecules、Mol Cancer、Mol Med Rep、Mol Pharmacol、Mol Pharm、Nanomed-Nanotec、Oncotarget、Onco Targets Ther、Oncol Rep、Oncol Lett、Open Bio、Pathol Res Pract、Patient Prefer Adher、Peer J、Plos One、Pharmaceuticals、Pharmacol Res、Phytomedicine、Rencent Pat Anti-Cancer、RSC Adv、 RSC Med Chem、Sci Rep、Signal Transduct Target Ther、Technol Cancer Res Treat、Tissue Cell、Theranostics、Ther Clin Risk Manag、Tumor Bio、World J Gastroenterol.

4. 基金/獎(jiǎng)勵(lì)評(píng)審人：

國(guó)家自然科學(xué)基金、中國(guó)博士后科學(xué)基金、廣東省自然科學(xué)基金、廣東省科技計(jì)劃項(xiàng)目、廣東省科技獎(jiǎng)、河北省自然科學(xué)基金、湖北省自然科學(xué)基金、江蘇省自然科學(xué)基金、浙江省自然科學(xué)基金、江西省基礎(chǔ)研究計(jì)劃項(xiàng)目、東莞市科技計(jì)劃項(xiàng)目、東莞市科技獎(jiǎng)。

講授課程：

《分子細(xì)胞生物學(xué)》、《細(xì)胞生物學(xué)》、《生物工程制藥》和《腫瘤分子生物學(xué)》等。

研究生培養(yǎng)情況：

已培養(yǎng)博士研究生4名、碩士研究生13人，在培養(yǎng)博士研究生4人、碩士研究生10人，其中9人次獲得國(guó)家獎(jiǎng)學(xué)金。

研究方向：

腫瘤發(fā)生發(fā)展的機(jī)制及抗腫瘤藥物開發(fā)。

承擔(dān)科研項(xiàng)目情況：

主持國(guó)家重點(diǎn)研發(fā)計(jì)劃子課題、國(guó)家自然科學(xué)基金、廣東省自然科學(xué)杰出青年基金、廣東省科技計(jì)劃項(xiàng)目和廣州市產(chǎn)學(xué)研協(xié)同創(chuàng)新重大專項(xiàng)等15項(xiàng)基金。

1. 國(guó)家自然科學(xué)基金（No. 31271444）：抑癌蛋白Cables1 的磷酸化及其在細(xì)胞周期調(diào)控中的作用，2013.1-2016.12， 80萬，主持。

2. 國(guó)家自然科學(xué)基金（No. 81201726）：西地那非抗結(jié)直腸癌的作用及其機(jī)制研究，2013.1-2015.12， 23萬，主持。

3. 教育部高等學(xué)校博士學(xué)科點(diǎn)專項(xiàng)科研基金（No. 20124401120007）：抑癌蛋白Cables1的磷酸化修飾及其調(diào)控細(xì)胞周期的作用機(jī)制，2013.1-2015.12，4萬，主持。

4. 暨南大學(xué)科研培育與創(chuàng)新基金（No. 21612407）：抑癌蛋白Cables1的磷酸化修飾及其調(diào)控細(xì)胞周期的作用機(jī)制，2012.1-2013.12， 10萬，主持。

科研成果：

1. 2012年度廣東省科學(xué)技術(shù)獎(jiǎng)一等獎(jiǎng)，克服ABC藥物轉(zhuǎn)運(yùn)泵介導(dǎo)的腫瘤多藥抗藥性的研究，第三完成人。

2. 2012年度中華醫(yī)學(xué)科技獎(jiǎng)三等獎(jiǎng)，克服ABC藥物轉(zhuǎn)運(yùn)泵介導(dǎo)的腫瘤多藥抗藥性的研究，第三完成人。

3. 2011年度中國(guó)抗癌協(xié)會(huì)科技獎(jiǎng)一等獎(jiǎng)，克服ABC藥物轉(zhuǎn)運(yùn)泵介導(dǎo)的腫瘤多藥抗藥性的研究，排名第三 。

4. 2011年度高等學(xué)�？茖W(xué)研究?jī)?yōu)秀成果獎(jiǎng)二等獎(jiǎng)，克服ABC藥物轉(zhuǎn)運(yùn)泵介導(dǎo)的腫瘤多藥抗藥性的研究，排名第三。

5. 2009年度廣東省優(yōu)秀博士論文，多種策略逆轉(zhuǎn)P-糖蛋白和乳腺癌耐藥相關(guān)蛋白介導(dǎo)的腫瘤多藥耐藥。

認(rèn)定成果：

1 抗腫瘤干細(xì)胞標(biāo)志蛋白CD44人源單鏈抗體新藥CD44-207的臨床前研究 魏星;石智;周玉英;郭淑軍;劉志芳;陳濤;劉雪;洪海峰;崔海青;林澤雄 暨南大學(xué) 2019

2 靶向uPAR克服腫瘤多藥耐藥的應(yīng)用研究 石智;王仁友;Zhe-ShengChen;張文姬;蔣起韋;楊陽;鄭迪威;陳耀;王昆;黃家榮 暨南大學(xué) 2019

3 uPAR在腫瘤多藥耐藥中的作用及機(jī)制研究 石智;Zhe-Sheng Chen;郭淑軍;邱建閣;張文姬;蔣起韋;楊陽;鄭迪威;陳耀 暨南大學(xué) 2018

4 AKT激酶磷酸化Cables1蛋白調(diào)控細(xì)胞周期在腫瘤治療中的作用和機(jī)制研究 石智 暨南大學(xué) 2018

5 畬藥質(zhì)量控制關(guān)鍵技術(shù)研究及應(yīng)用 程科軍;石智;王奎武;呂群丹;黃剛;楊國(guó)勛;潘俊杰;金葉;陳正道;胡金鋒;姚輝;方潔;王偉影;程文亮;徐金標(biāo);毛菊華;俞培忠 麗水市農(nóng)業(yè)科學(xué)研究院 2016

6 天然產(chǎn)物蓽茇酰胺治療腫瘤的機(jī)制及其應(yīng)用 潘峰;陳曉釬;劉迪;石智;陳勇;劉菊梅;熊昕昕;邱辛瑤;劉倩蓉;陳若喬;余上斌;謝小強(qiáng);胡殿興;劉鋒;李春陽 華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬協(xié)和醫(yī)院 2016

7 抗體--美登素藥物偶聯(lián)關(guān)鍵技術(shù)研究 魏星;李勝峰;石智;張玲;郭淑軍;余守和;馬歡;徐光祖;俞金泉;鄧小斌 暨南大學(xué) 2015

8 抗腫瘤干細(xì)胞標(biāo)志蛋白CD44人源抗體新藥HM-302的臨床前研究及其規(guī)模制備技術(shù) 魏星;石智;郭淑軍;周玉英;余守和;馬歡;蘇仲春;張偉雄;吳伯剛;劉靜 暨南大學(xué)生命科學(xué)技術(shù)學(xué)院 2016

9 抗腫瘤干細(xì)胞標(biāo)志蛋白CD44人源抗體新藥HM-302的臨床前研究及其規(guī)模制備技術(shù) 魏星;石智;郭淑軍;周玉英;余守和;馬歡;蘇仲春;張偉雄;吳伯剛;劉靜 暨南大學(xué)生命科學(xué)技術(shù)學(xué)院 2016

10 珍稀藥用植物新穎化學(xué)成分及藥理活性研究 徐金標(biāo);程科軍;呂群丹;毛菊華;王鴻;朱波;余華麗;方潔;余樂;王偉影;石智;程文亮;陳張金;潘俊杰;范耀月;呂敏;范芳娟;吉慶勇 麗水市農(nóng)業(yè)科學(xué)研究院 2015

11 常用畬藥物質(zhì)基礎(chǔ)研究及質(zhì)量標(biāo)準(zhǔn)制定 程科軍;李水福;王偉影;范蕾;劉敏;徐金標(biāo);呂群丹;王鴻;毛菊華;方潔;石智;姚輝;程文亮;姜程曦;姚宏;吉慶勇;溫慧萍;潘俊杰 麗水市農(nóng)業(yè)科學(xué)研究院 2014

12 克服ABC轉(zhuǎn)運(yùn)泵介導(dǎo)的腫瘤多藥抗藥性的研究 符立梧;梁永鉅;石智;戴春嶺;閆燕艷;陳黎明 中山大學(xué)腫瘤防治中心 2009

13 RNAi及其在腫瘤研究中的應(yīng)用 石智;符立梧 中山大學(xué) 2009

美國(guó)發(fā)明專利：

1. Use of phosphodiesterase inhibitors for treating multidrug resistance.申請(qǐng)美國(guó)專利：13/432,315；2011年。  

中國(guó)發(fā)明公開：

[1]徐石海, 黃知涵, 張學(xué)敏, 石智. 一種環(huán)五肽Galaxamide與阿霉素的抗腫瘤組合藥物及其應(yīng)用[P]. 廣東省: CN116270967A, 2023-06-23.

[2]石智, 邢自豪. 一種多組學(xué)數(shù)據(jù)整合分析方法和在線交互式綜合分析平臺(tái)[P]. 廣東省: CN114203259A, 2022-03-18.

[3]石智, 劉坤. KU55933在制備逆轉(zhuǎn)腫瘤多藥耐藥性藥物中的應(yīng)用[P]. 廣東省: CN112972477A, 2021-06-18.

[4]石智, 黃家榮. CDK7抑制劑在制備潰瘍性結(jié)腸炎或結(jié)腸癌藥物的應(yīng)用[P]. 廣東省: CN110101703A, 2019-08-09.

[5]石智, 陳耀, 張文姬, 魏夢(mèng)寧, 邱建閣, 蔣起韋, 楊陽, 鄭迪威, 王昆, 黃家榮. 一種特異靶向人ABCG2基因的sgRNA導(dǎo)向序列及其應(yīng)用[P]. 廣東: CN106191061A, 2016-12-07.

[6]石智, 楊陽, 邱建閣, 張文姬, 蔣起韋, 覃武明, 陳耀, 鄭迪威, 魏夢(mèng)寧. 一種特異靶向人ABCB1基因的sgRNA導(dǎo)向序列及應(yīng)用[P]. 廣東: CN105441451A, 2016-03-30.

[7]石智, 張文姬, 陳耀, 魏夢(mèng)寧, 邱建閣, 蔣起韋, 覃武明, 楊陽, 鄭迪威. 瑞格替尼和拉帕替尼在制備抗腫瘤聯(lián)合用藥物中的應(yīng)用[P]. 廣東: CN105343095A, 2016-02-24.

[8]程科軍, 俞培忠, 石智, 張鵬, 胡昌奇, 程文亮. 孕甾烷生物堿及其制備方法和在制備抗腫瘤藥物中的用途[P]. 上海: CN104804057A, 2015-07-29.

[9]俞培忠, 程科軍, 石智, 胡昌奇. 清香桂總生物堿及其制備方法和用途[P]. 上海: CN104666374A, 2015-06-03.

[10]石智, 邱建閣, 梅曉龍, 張文姬, 覃武明. 曲美替尼在制備逆轉(zhuǎn)腫瘤多藥耐藥性藥物中的應(yīng)用[P]. 廣東: CN104434924A, 2015-03-25.

[11]石智, 蔣起韋, 程科軍, 魏星, 呂敏, 張旭. 雷公藤甲素和雷公藤紅素在制備抗腫瘤藥物中的應(yīng)用[P]. 廣東: CN104398526A, 2015-03-11.

[12]程科軍, 胡昌奇, 俞培忠, 李煒, 石智, 程文亮, 陳張金. 白藜蘆醇三聚體茋類化合物及其制備方法和抗腫瘤用途[P]. 浙江: CN103467476A, 2013-12-25. 

中國(guó)發(fā)明授權(quán)：

[1]石智, 邢自豪. 一種多組學(xué)數(shù)據(jù)整合分析方法和在線交互式綜合分析平臺(tái)[P]. 廣東省: CN114203259B, 2024-05-17.

[2]石智, 劉坤. KU55933在制備逆轉(zhuǎn)腫瘤多藥耐藥性藥物中的應(yīng)用[P]. 廣東省: CN112972477B, 2023-05-30.

[3]石智, 黃家榮. CDK7抑制劑在制備潰瘍性結(jié)腸炎或結(jié)腸癌藥物的應(yīng)用[P]. 廣東省: CN110101703B, 2021-06-11.

[4]石智, 陳耀, 張文姬, 魏夢(mèng)寧, 邱建閣, 蔣起韋, 楊陽, 鄭迪威, 王昆, 黃家榮. 一種特異靶向人ABCG2基因的sgRNA導(dǎo)向序列及其應(yīng)用[P]. 廣東省: CN106191061B, 2019-06-18.

[5]石智, 楊陽, 邱建閣, 張文姬, 蔣起韋, 覃武明, 陳耀, 鄭迪威, 魏夢(mèng)寧. 一種特異靶向人ABCB1基因的sgRNA導(dǎo)向序列及應(yīng)用[P]. 廣東省: CN105441451B, 2019-03-22.

[6]石智, 蔣起韋, 程科軍, 魏星, 呂敏, 張旭. 雷公藤甲素和雷公藤紅素在制備抗腫瘤藥物中的應(yīng)用[P]. 廣東省: CN104398526B, 2017-12-19.

[7]程科軍, 俞培忠, 石智, 張鵬, 胡昌奇, 程文亮. 孕甾烷生物堿及其制備方法和在制備抗腫瘤藥物中的用途[P]. 上海市: CN104804057B, 2017-11-07.

[8]石智, 邱建閣, 梅曉龍, 張文姬, 覃武明. 曲美替尼在制備逆轉(zhuǎn)腫瘤多藥耐藥性藥物中的應(yīng)用[P]. 廣東省: CN104434924B, 2016-09-14.

[9]程科軍, 胡昌奇, 俞培忠, 李煒, 石智, 程文亮, 陳張金. 白藜蘆醇三聚體茋類化合物及其制備方法和抗腫瘤用途[P]. 浙江省: CN103467476B, 2016-08-10.

 

以第一和通訊作者（含共同）在Signal Transduct Target Ther、Cancer Res（4篇）、Oncogene、J Biol Chem、Br J Pharmacol、Cancer Lett （2篇）、Biotechnol Adv、Med Res Rev、Trends Cancer和Drug Discov Today（2篇）等期刊發(fā)表SCI論文56篇，總影響因子280點(diǎn)，Google學(xué)術(shù)中被Nat Rev Cancer、Nat Rev Drug Discov等期刊引用2496次，單篇最高320次，另以合作作者發(fā)表SCI論文28篇，H指數(shù)40，英文書籍章節(jié)3篇。。

主要著作：

[1]Yang Yang, Zhi Shi*. “STAT3 Inhibitors as Sensitizing Agents for Cancer Chemotherapy.”, Book Title: “Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy.” Academic Press. ISBN: 9780128164358. 2018-12-03. 

[2]Jian-Ge Qiu, Xiao-Long Mei, Zhe-Sheng Chen*, Zhi Shi*. “Cytokine detection by flow cytometry.”, Book Title: “Methods in Molecular Biology”, Volume “Cytokine Bioassays: Methods and Protocol”. 2014;1172:235-242. Humana Press.ISBN: 978-1-4939-0928-5. 2014-05-19.

[3]Zhi Shi#, Amit K. Tiwari#, Charles R. Ashby Jr., Liwu Fu, Zhe-Sheng Chen, “Anticancer role of Phosphodiesterase-5 inhibitors.”, Book Title: “The Research and Biology of Cancer”. 2013, iConcept Press Ltd. ISBN: 978-1-922227-22-5.

代表性英文論文：

[1]Jiang, Qiwei; Li, Yong; Cai, Songwang; Shi, Xingyuan; Yang, Yang; Xing, Zihao; He, Zhenjie; Wang, Shengte; Su, Yubin; Chen, Meiwan; Chen, Zhesheng; Shi, Zhi*.GLUL stabilizes N-Cadherin by antagonizing β-Catenin to inhibit the progresses of gastric cancer.Acta Pharmaceutica Sinica B, 2024, 14(2): 698-711.

[2]Yu, Ze-Zhong; Xu, Bu-Qing; Wang, Ying-Ying; Zhang, Peng-Wei; Shu, Yu-Bin; Shi, Zhi*.GSK2606414 Sensitizes ABCG2-Overexpressing Multidrug-Resistant Colorectal Cancer Cells to Chemotherapeutic Drugs.Biomedicines, 2023, 11(11): 3103.

[3]Liu, Wen-Jing; Wang, Lin; Zhou, Feng-Mei; Liu, Shu-Wen; Wang, Wei; Zhao, Er-Jiang; Yao, Quan-Jun; Li, Wei; Zhao, Yan-Qiu; Shi, Zhi; Qiu, Jian-Ge*; Jiang, Bing-Hua*.Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC.Drug Resistance Updates, 2023, 70: 100987.

[4]Shi, Zhi*; Wang, Ning*; Zhang, Ying-Jie*; Zheng, Yi-Chao*.Editorial: Epigenetic mechanisms and post-translational modifications as novel therapeutic targets in cancer.Frontiers in Pharmacology, 2022, 13: 988334.

[5]Yang, Suleixin; Wong, Ka Hong; Hua, Peng; He, Chengwei; Yu, Hua; Shao, Dan; Shi, Zhi; Chen, Meiwan*.ROS-responsive fluorinated polyethyleneimine vector to co-deliver shMTHFD2 and shGPX4 plasmids induces ferroptosis and apoptosis for cancer therapy.Acta Biomaterialia, 2022, 140: 492-505.

[6]Li, Yan-Chi#; Cai, Song-Wang#; Shu, Yu-Bin; Chen, Mei-Wan; Shi, Zhi*.USP15 in Cancer and Other Diseases: From Diverse Functionsto Therapeutic Targets.Biomedicines, 2022, 10(2): 474.

[7]Liu, Kun#; Chen, Yu#; Shi, Xiao-Bao#; Xing, Zi-Hao; He, Zheng-Jie; Wang, Sheng-Te; Li, Yan-Chi; Liu, Wei-Jing; Zhang, Peng-Wei; Yu, Ze-Zhong; Mo, Xue-Mei; Shi, Xing-Yuan*; Chen, Zhe-Sheng*; Shi, Zhi*.Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer.Recent Pat Anticancer Drug Discov, 2022.

[8]Wang, Jing-Quan; Wang, Bo; Ma, Li-Ying; Shi, Zhi; Liu, Hong-Min*; Liu, Zhijun*; Chen, Zhe-Sheng*.Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin.Experimental Cell Research, 2021, 405(2): 112728.

[9]Wang, Jing-Quan; Wang, Bo; Teng, Qiu-Xu; Lei, Zi-Ning; Li, Yi-Dong; Shi, Zhi; Ma, Li-Ying; Liu, Hong-Min*; Liu, Zhijun*; Chen, Zhe-Sheng*.CMP25, a synthetic new agent, targets multidrug resistance-associated protein 7 (MRP7/ABCC10).Biochemical Pharmacology, 2021, 190: 114652.

[10]Liu, Kun; Li, Yan-Chi; Chen, Yu; Shi, Xiao-Bao; Xing, Zi-Hao; He, Zheng-Jie; Wang, Sheng-Te; Liu, Wei-Jing; Zhang, Peng-Wei; Yu, Ze-Zhong; Mo, Xue-Mei; Chen, Mei-Wan*; Chen, Zhe-Sheng*; Shi, Zhi*.AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer.Frontiers in Oncology, 2021, 11: 680663.

[11]Diwei Zheng#; Weihai Liu#; Wenlin Xie#; Guanyu Huang#; Qiwei Jiang; Yang Yang; Jiarong Huang; Zihao Xing; Mengling Yuan; Mengning Wei; Yao Li; Junqiang Yin*; Jingnan Shen*; Zhi Shi*.AHA1 upregulates IDH1 and metabolic activity to promote growth and metastasis and predicts prognosis in osteosarcoma.Signal Transduction and Targeted Therapy, 2021, 6(25).6:25. (SCI IF: 18.187)

[12]Yang Suleixin; Wong Ka Hong; Hua Peng; He Chengwei; Yu Hua; Shao Dan; Shi Zhi; Chen Meiwan.ROS-responsive Fluorinated Polyethyleneimine Vector to Co-deliver shMTHFD2 and shGPX4 Plasmids Induces Ferroptosis and Apoptosis for Cancer Therapy.Acta Biomaterialia, 2021, 140.

[13]Huang JR#; Wang ST#; Wei MN; Liu K; Fu JW; Xing ZH; Shi Z*.Piperlongumine alleviates mouse colitis and colitis-associated colorectal cancer.Frontiers in Pharmacology, 2020, 10(1): 3389.

[14]Li WS; Yan RJ; Yu Y; Shi Z; Mándi A; Shen L*; Kurtán T*; Wu J*.Determination of the Absolute Configuration of Super-Carbon-Chain Compounds by a Combined Chemical, Spectroscopic, and Computational Approach: Gibbosols A and B.Angewandte Chemie - International Edition, 2020, 59(31): 13028-13036.

[15]Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q*; Yin J*; Shen J*.Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.Clinical Cancer Research, 2020, 26(11): 2681-2692.

[16]Jiang Y; Xing Z; Zhu B; Wang W; Sun Y; Shi Z*; Li Z*.Multi-omic analysis reveals HIP-55-dependent regulation of cytokines release.Bioscience Reports, 2020, 40(3).

[17]Lin XJ#; Liu H#; Li P#; Wang HF#; Yang AK; Di JM; Jiang QW; Yang Y; Huang JR; Yuan ML; Xing ZH; Wei MN; Li Y*; Shi Z*; Ye J*.miR-936 Suppresses Cell Proliferation, Invasion, and Drug Resistance of Laryngeal Squamous Cell Carcinoma and Targets GPR78.Frontiers in Oncology, 2020, 10(1): 60.

[18]Zhang, Wenji#; Yang, Yang#; Dong, Zizheng; Shi, Zhi*; Zhang, Jian-Ting*.Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs.JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294(52): 20222-20232. (SCI IF: 4.238)

[19]Li, Pei#; Lin, Xi-Jun#; Yang, Yang#; Yang, An-Kui; Di, Jin-Ming; Jiang, Qi-Wei; Huang, Jia-Rong; Yuan, Meng-Ling; Xing, Zi-Hao; Wei, Meng-Ning; Li, Yao; Yuan, Xiao-Hui; Shi, Zhi*; Liu, Hui*; Ye, Jin*.Reciprocal regulation of miR-1205 and E2F1 modulates progression of laryngeal squamous cell carcinoma.Cell Death & Disease, 2019, 10(12): 916.

[20]Jiang, Qi wei; Kaili, Denis; Freeman, Jonaye; Lei, Chong yang; Geng, Bing chuan; Tan, Tao; He, Jian feng; Shi, Zhi; Ma, Jian jie; Luo, Yan hong*; Chandler, Heather*; Zhu, Hua*.Diabetes inhibits corneal epithelial cell migration and tight junction formation in mice and human via increasing ROS and impairing Akt signaling.Acta Pharmacologica Sinica, 2019, 40(9): 1205-1211.

[21]Shi, Zhi*; Guo, Hui Qin; Cohen, Pascale A; Yang, Dong Hua*.Editorial: Novel Targets and Biomarkers in Solid Tumors.Frontiers in Pharmacology, 2019, 10: 828. 

[22]Wang, Kun#; Xing, Zihao#; Jiang, Qiwei; Yang, Yang; Huang, Jiarong; Yuan, Mengling; Wei, Mengning; Li, Yao; Wang, Shengte; Liu, Kun; Shi, Zhi*.Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance.Frontiers in Oncology, 2019, 9(1): 80.

[23]Qiu Jiange; Li Qianqian; Bell Katherine A; Yao Xue; Du Yifeng; Zhang Erik; Yu Jane J; Yu Ying; Shi Zhi*; Jiang Jianxiong*.Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth.British Journal of Pharmacology, 2019, 176(11): 1680-1699. (SCI IF: 7.730)

[24]Zhang, Yun Kai; Wang, Yi Jun; Lei, Zi Ning; Zhang, Guan Nan; Zhang, Xiao Yu; Wang, De shen; Al Rihani, Sweilem B; Shukla, Suneet; Ambudkar, Suresh V; Kaddoumi, Amal; Shi, Zhi; Chen, Zhe Sheng*.Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.Cancer Letters, 2019, 442: 104-112.

[25]Nan, Xing-Wei#; Gong, Li-Hua#; Chen, Xu#; Shi, Zhi#; Yan, Xiao-Jian#; Zhou, Hai-Hong; Ye, Piao-Piao; Yang, Yang; Xing, Zi-Hao; Wei, Meng-Ning; Li, Yao; Wang, Sheng-Te; Liu, Kun.Survivin Promotes Piperlongumine Resistance in Ovarian Cancer.Frontiers in Oncology, 2019, 9(1): 1345.

[26]Huang, Shan-Zhou#; Wei, Meng-Ning#; Huang, Jia-Rong#; Zhang, Zi-Jian; Zhang, Wen-Ji; Jiang, Qi-Wei; Yang, Yang; Wang, Huan-Yu; Jin, Hui-Lin; Wang, Kun; Xing, Zi-Hao; Yuan, Meng-Ling; Li, Yao; He, Xiao-Shun*; Shi, Zhi*; Zhou, Qi*.Targeting TF-AKT/ERK-EGFR Pathway Suppresses the Growth of Hepatocellular Carcinoma.Frontiers in Oncology, 2019, 9(1): 150.

[27]Zhou, Hai-Hong#; Chen, Xu#; Cai, Lu-Ya#; Nan, Xing-Wei; Chen, Jia-Hua; Chen, Xiu-Xiu; Yang, Yang; Xing, Zi-Hao; Wei, Meng-Ning; Li, Yao; Wang, Sheng-Te; Liu, Kun; Shi, Zhi*; Yan, Xiao-Jian*.Erastin reverses ABCB1-mediated docetaxel resistance in ovarian cancer.Frontiers in Oncology, 2019, 9(1): 1358.

[28]Xu Lina#; Zhao Na#; Chen Jinyan#; Ye Piaopiao; Nan Xingwei; Zhou Haihong; Jiang Qiwei; Yang Yang; Huang Jiarong; Yuan Mengling; Xing Zihao; Wei Mengning; Li Yao; Shi Zhi*; Yan Xiao Jian*.Celastrol Inhibits the Growth of Ovarian Cancer Cells in vitro and in vivo.Frontiers in Oncology, 2019, 9(1): 2.

[29]Huang, Shanzhou; Zhong, Wenqiang; Shi, Zhi; Wang, Kun; Jin, Huilin; Zhang, Zijian; Wang, Huanyu; Wei, Yongcheng; Chen, Sixv; Zhou, Qi*; He, Xiaoshun*.Overexpression of signal sequence receptor gamma predicts poor survival in patients with hepatocellular carcinoma.Human Pathology, 2018, 81: 47-54. 

[30]Zhang Wenji; Sun Shili; Zhang Wenjuan*; Shi Zhi*.Polymorphisms of ABCG2 and its impact on clinical relevance.Biochem Biophys Res Commun, 2018, 503(2): 408-413. 

[31]Zhang, Min; Shi, Zhi; Liu, Junjun; Shen, Li*; Wu, Jun*.New 30-ketophragmalins with anti-breast cancer activity against MDA-MB-453 cells from the Godavari mangrove, Xylocarpus moluccensis (Lam.) M. Roem.Phytochemistry Letters, 2018, 26: 143-148. 

[32]Zhang Xiao-Hui#; Yang Yang#; Liu Jun-Jun; Shen Li*; Shi Zhi*; Wu Jun*.Tagalide A and tagalol A, naturally occurring 5/6/6/6-and 5/6/6-fused cyclic dolabrane-type diterpenes: a new insight into the anti-breast cancer activity of the dolabrane scaffold.Organic Chemistry Frontiers, 2018, 5(7): 1176-1183.

[33]Li Wan-Shan#; Yang Yang#; Liu Jun-Jun; Shen Li*; Shi Zhi*; Wu Jun*.Scaffold diversity-oriented synthesis of limonoid dimers: discovery of an axially chiral agent with in vivo anti-breast cancer activity.Organic Chemistry Frontiers, 2018, 5(7): 1079-1091. 

[34]Ye Jin#; Zou Manman#; Li Pei; Lin Xijun; Jiang Qiwei; Yang Yang; Huang Jiarong; Yuan Mengling; Xing Zihao; Wei Mengning; Li Yao; Shi Zhi*; Liu Hui*.Oxymatrine and Cisplatin Synergistically Enhance Anti-tumor Immunity of CD8(+) T Cells in Non-small Cell Lung Cancer.Frontiers in Oncology, 2018, 8(1): 631. 

[35]Yuan Meng-Ling#; Li Pei#; Xing Zi-Hao; Di Jin-Ming; Liu Hui; Yang An-Kui; Lin Xi-Jun; Jiang Qi-Wei; Yang Yang; Huang Jia-Rong; Wang Kun; Wei Meng-Ning; Li Yao; Ye Jin*; Shi Zhi*.Inhibition of WEE1 Suppresses the Tumor Growth in Laryngeal Squamous Cell Carcinoma.Frontiers in Pharmacology, 2018, 9(1): 1041.

[36]Huang Jia-Rong#; Qin Wu-Ming#; Wang Kun; Fu Deng-Rui; Zhang Wen-Ji; Jiang Qi-Wei; Yang Yang; Yuan Meng-Ling; Xing Zi-Hao; Wei Meng-Ning; Li Yao; Shi Zhi*.Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancer in vitro and in vivo.American Journal of Translational Research, 2018, 10(11): 3664-3676.

[37]Hou Li-Jiao#; Huang Xiao-Xiu#; Xu Li-Na; Zhang Yan-Yan; Zhao Na; Ou Rong-Ying; Li Wen-Feng; Zhang Wen-Ji; Jiang Qi-Wei; Yang Yang; Wei Meng-Ning; Huang Jia-Rong; Wang Kun; Yuan Meng-Ling; Xing Zi-Hao; Shi Zhi*; Yan Xiao-Jian*.YM155 enhances docetaxel efficacy in ovarian cancer.American Journal of Translational Research, 2018, 10(3): 696-708.

[38]Zhang, Jinming; Li, Jingjing; Shi, Zhi; Yang, Yang; Xie, Xi; Lee, Simon MingYuen*; Wang, Yitao; Leong, Kam W; Chen, Meiwan.pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.Acta Biomaterialia, 2017, 58: 349-364. 

[39]Cai, Yuee; Zhang, Jinming; Chen, Nelson G.; Shi, Zhi; Qiu, Jiange; He, Chengwei; Chen, Meiwan*.Recent Advances in Anticancer Activities and Drug Delivery Systems of Tannins.Medicinal Research Reviews, 2017, 37(4): 665-701.

[40]Wang, Yi-Jun; Zhang, Yun-Kai; Zhang, Guan-Nan; Al Rihani, Sweilem B.; Wei, Meng-Ning; Gupta, Pranav; Zhang, Xiao-Yu; Shukla, Suneet; Ambudkar, Suresh V.; Kaddoumi, Amal; Shi, Zhi*; Chen, Zhe-Sheng*.Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.Cancer Letters, 2017, 396: 145-154. (SCI IF: 6.491)

[41]Zhang, Wen-Ji; Li, Yong; Wei, Meng-Ning; Chen, Yao; Qiu, Jian-Ge; Jiang, Qi-Wei; Yang, Yang; Zheng, Di-Wei; Qin, Wu-Ming; Huang, Jia-Rong; Wang, Kun; Zhang, Wen-Juan; Wang, Yi-Jun; Yang, Dong-Hua; Chen, Zhe-Sheng*; Shi, Zhi*.Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.Cancer Letters, 2017, 386: 100-109. (SCI IF: 6.491)

[42]Jianxiong Jiang*; Jiange Qiu; Qianqian Li; Zhi Shi*.Prostaglandin E2 Signaling: Alternative Target for Glioblastoma?Trends in Cancer, 2017, 3(2): 75-78. (SCI IF: 7.038)

[43]Li, Pei#; Yang, Yang#; Liu, Hui#; Yang, An-Kui; Di, Jin-Ming; Tan, Guang-Mou; Wang, Hai-Feng; Qiu, Jian-Ge; Zhang, Wen-Ji; Jiang, Qi-Wei; Zheng, Di-Wei; Chen, Yao; Wei, Meng-Ning; Huang, Jia-Rong; Wang, Kun; Shi, Zhi*; Ye, Jin*.MiR-194 functions as a tumor suppressor in laryngeal squamous cell carcinoma by targeting Wee1.Journal of Hematology & Oncology, 2017, 10(1): 32-32.

[44]Huang, Jia-Rong#; Tan, Guang-Mou#; Li, Yong; Shi, Zhi*.The emerging role of Cables1 in cancer and other diseases.Molecular Pharmacology, 2017, 92(7): 1-6.

[45]Qiu, Jiange; Shi, Zhi*; Jiang, Jianxiong*.Cyclooxygenase-2 in glioblastoma multiforme.Drug Discovery Today, 2017, 22(1): 148-156. (SCI IF: 6.848).

[46]Peng, Qi-Qi#; Wang, Kun#; Cheng, Ke-Jun#; Yang, Hai-Gan; Qiu, Jian-Ge; Zhang, Wen-Ji; Jiang, Qi-Wei; Yang, Yang; Zheng, Di-Wei; Huang, Jia-Rong; Wei, Meng-Ning; Shi, Zhi*; Wang, Wei*.Caragaphenol a induces reactive oxygen species related apoptosis in human gastric cancer cells.American Journal of Translational Research, 2017, 9(8): 3804-3815.

[47]Huang, Xiao-Xiu#; Xie, Feng-Feng#; Hou, Li-Jiao; Chen, Xiu-Xiu; Ou, Rong-Ying; Yu, Jiang-Tao; Qiu, Jian-Ge; Zhang, Wen-Ji; Jiang, Qi-Wei; Yang, Yang; Zheng, Di-Wei; Chen, Yao; Huang, Jia-Rong; Wang, Kun; Wei, Meng-Ning; Li, Wen-Feng; Shi, Zhi*; Yan, Xiao-Jian*.Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer.American Journal of Translational Research, 2017, 9(4): 1667-1679.

[48]Chen, XiuXiu#; Gong, LiHua#; Ou, RongYing; Zheng, ZhenZhen; Chen, JinYan; Xie, FengFeng; Huang, XiaoXiu; Qiu, JianGe; Zhang, WenJi; Jiang, QiWei; Yang, Yang; Zhu, Hua; Shi, Zhi*; Yan, XiaoJian*.Sequential combination therapy of ovarian cancer with cisplatin and gamma-secretase inhibitor MK-0752.Gynecologic Oncology, 2016, 140(3): 537-544.

[49]He, Weiwen#; Wu, Yanna#; Tang, Xiaomei; Xia, Yong; He, Guozhen; Min, Zhiqun; Li, Chun; Xiong, Shiqiu; Shi, Zhi; Lu, Yongjian; Yuan, Zhongmin*.HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells.Oncotarget, 2016, 6(17): 6727-6747.

[50]Jiang, Qi-Wei#; Chen, Mei-Wan#; Cheng, Ke-Jun#; Yu, Pei-Zhong; Wei, Xing; Shi, Zhi*.Therapeutic Potential of Steroidal Alkaloids in Cancer and Other Diseases.Medicinal Research Reviews, 2016, 36(1): 119-143. (SCI IF: 8.763)

[51]Luo, Yun#; Wu, Jie-Ying#; Hou, Guo-Liang; Lu, Min-Hua; Shi, Zhi; Di, Jin-Ming*.ODAM is a predictor for biomedical recurrence and inhibits the migration and invasion of prostate cancer.American Journal of Translational Research, 2016, 8(2): 670-679.

[52]Li, Pei#; Liu, Hui#; Wang, Zhiyuan; He, Feng; Wang, Haifeng; Shi, Zhi; Yang, Ankui*; Ye, Jin*.MicroRNAs in laryngeal cancer: implications for diagnosis, prognosis and therapy.American Journal of Translational Research, 2016, 8(5): 1935-1944.

[53]Luo, Yun#; Wu, Jie-Ying#; Lu, Min-Hua; Shi, Zhi; Na, Ning*; Di, Jin-Ming*。Carvacrol Alleviates Prostate Cancer Cell Proliferation, Migration, and Invasion through Regulation of PI3K/Akt and MAPK Signaling Pathways.Oxidative Medicine and Cellular Longevity, 2016, 2016: 1469693-1469693.

[54]Yang, Yang#; Qiu, Jian-Ge#; Li, Yong#; Di, Jin-Ming; Zhang, Wen-Ji; Jiang, Qi-Wei; Zheng, Di-Wei; Chen, Yao; Wei, Meng-Ning; Huang, Jia-Rong; Wang, Kun; Shi, Zhi*。Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing.American Journal of Translational Research, 2016, 8(9): 3986-3994. 

[55]Lv, Min#; Qiu, Jian-Ge#; Zhang, Wen-Ji; Jiang, Qi-Wei; Qin, Wu-Ming; Yang, Yang; Zheng, Di-Wei; Chen, Yao; Huang, Jia-Rong; Wang, Kun; Wei, Meng-Ning; Cheng, Ke-Jun*; Shi, Zhi*.Wallichinine reverses ABCB1-mediated cancer multidrug resistance.American Journal of Translational Research, 2016, 8(7): 2969-2980.

[56]Cai, Yuee#; Zhang, Wenji#; Chen, Zirong; Shi, Zhi*; He, Chengwei; Chen, Meiwan*.Recent insights into the biological activities and drug delivery systems of tanshinones.International Journal of Nanomedicine, 2016, 11: 121-130.

[57]Zhang, Peng; Shao, Luping; Shi, Zhi; Zhang, Yao; Du, Jiang; Cheng, Kejun*; Yu, Peizhong*.Pregnane alkaloids from Sarcococca ruscifolia and their cytotoxic activity.Phytochemistry Letters, 2015, 14: 31-34. 

[58]Jiang, Qi-Wei#; Cheng, Ke-Jun#; Mei, Xiao-Long; Qiu, Jian-Ge; Zhang, Wen-Ji; Xue, You-Qiu; Qin, Wu-Ming; Yang, Yang; Zheng, Di-Wei; Chen, Yao; Wei, Meng-Ning; Zhang, Xu; Lv, Min; Chen, Mei-Wan; Wei, Xing; Shi, Zhi*.Synergistic anticancer effects of triptolide and celastrol, two main compounds from thunder god vine.Oncotarget, 2015, 6(32): 32790-32804.

[59]Luo, Yun#; Jiang, Qi-Wei#; Wu, Jie-Ying#; Qiu, Jian-Ge; Zhang, Wen-Ji; Mei, Xiao-Long; Shi, Zhi*; Di, Jin-Ming*.Regulation of migration and invasion by Toll-like receptor-9 signaling network in prostate cancer.Oncotarget, 2015, 6(26): 22564-22574. 

[60]Chen, Xiu-Xiu#; Xie, Feng-Feng#; Zhu, Xiu-Jie; Lin, Feng; Pan, Shi-Shi; Gong, Li-Hua; Qiu, Jian-Ge; Zhang, Wen-Ji; Jiang, Qi-Wei; Mei, Xiao-Long; Xue, You-Qiu; Qin, Wu-Ming; Shi, Zhi*; Yan, Xiao-Jian*.Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.Oncotarget, 2015, 6(17): 14926-14939. 

[61]Qiu, Jian-Ge; Zhang, Yao-Jun; Li, Yong; Zhao, Jin-Ming; Zhang, Wen-Ji; Jiang, Qi-Wei; Mei, Xiao-Long; Xue, You-Qiu; Qin, Wu-Ming; Yang, Yang; Zheng, Di-Wei; Chen, Yao; Wei, Meng-Ning; Shi, Zhi*.Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.Oncotarget, 2015, 6(17): 15494-15509.

[62]Shi, Z; Li, Z; Li, Z J; Cheng, K; Du, Y; Fu, H*; Khuri, F R*.Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3.Oncogene, 2015, 34(19): 2538-2545. (SCI IF: 7.932)

[63]Shi, Zhi#; Park, Hae R#; Du, Yuhong; Li, Zijian; Cheng, Kejun; Sun, Shi-Yong; Li, Zenggang; Fu, Haian*; Khuri, Fadlo R*.Cables1 complex couples survival signaling to the cell death machinery.Cancer Research, 2015, 75(1): 147-158.(SCI IF: 8.556)

[64]Ma, Yi*; Zhao, Shaojun; Shen, Shutao; Fang, Shixiong; Ye, Zulu; Shi, Zhi; Hong, An*.A novel recombinant slow-release TNF alpha-derived peptide effectively inhibits tumor growth and angiogensis.Scientific Reports, 2015, 5: 13595-13595.

[65]Xie, Feng-Feng#; Pan, Shi-Shi#; Ou, Rong-Ying#; Zheng, Zhen-Zhen; Huang, Xiao-Xiu; Jian, Meng-Ting; Qiu, Jian-Ge; Zhang, Wen-Ji; Jiang, Qi-Wei; Yang, Yang; Li, Wen-Feng; Shi, Zhi*; Yan, Xiao-Jian*.Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer.American Journal of Cancer Research, 2015, 5(12): 3548-3559.

[66]Mei, Xiao-Long#; Yang, Yang#; Zhang, Yao-Jun; Li, Yong; Zhao, Jin-Ming; Qiu, Jian-Ge; Zhang, Wen-Ji; Jiang, Qi-Wei; Xue, You-Qiu; Zheng, Di-Wei; Chen, Yao; Qin, Wu-Ming; Wei, Meng-Ning; Shi, Zhi*.Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo.American Journal of Cancer Research, 2015, 5(11): 3311-3324.

[67]Wang, Shengpeng; Qiu, Jiange; Shi, Zhi*; Wang, Yitao; Chen, Meiwan*.Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer.Biotechnology Advances, 2015, 33(1): 224-241. (SCI IF: 9.848)

[68]Yang, Chengzhi; Li, Zenggang; Shi, Zhi; He, Kangmin; Tian, Aiju; Wu, Jimin; Zhang, Youyi; Li, Zijian*.Regulation of cell survival by the HIP-55 signaling network.Molecular Biosystems, 2014, 10(6): 1393-1399. 

[69]Li, Zijian*; Park, Hae Ryon; Shi, Zhi; Li, Zenggang; Pham, Cau Dinh; Du, Yuhong; Khuri, Fadlo R; Zhang, Youyi; Han, Qide; Fu, Haian*.Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs.Oncotarget, 2014, 5(10): 3197-3209.

[70]Yan, Xiao-Jian#; Gong, Li-Hua#; Zheng, Fei-Yun; Cheng, Ke-Jun; Chen, Zhe-Sheng*; Shi, Zhi*.Triterpenoids as reversal agents for anticancer drug resistance treatment.Drug Discovery Today, 2014, 19(4): 482-488. (SCI IF: 6.691) 

[71]Wang, Shengpeng; Chen, Ruie; Zhong, Zhangfeng; Shi, Zhi; Chen, Meiwan*; Wang, Yitao*.Epigallocatechin-3-gallate potentiates the effect of curcumin in inducing growth inhibition and apoptosis of resistant breast cancer cells.American Journal of Chinese Medicine, 2014, 42(5): 1279-1300. 

[72]Wang, Shengpeng; Wang, Lu; Shi, Zhi; Zhong, Zhangfeng; Chen, Meiwan*; Wang, Yitao*.Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein.PLos One, 2014, 9(5).

[73]Xue, You-Qiu#; Di, Jin-Ming#; Luo, Yun#; Cheng, Ke-Jun; Wei, Xing*; Shi, Zhi*.Resveratrol oligomers for the prevention and treatment of cancers.Oxidative Medicine and Cellular Longevity, 2014, 2014: 765832-765832.

[74]Gong, Li-Hua#; Chen, Xiu-Xiu#; Wang, Huan; Jiang, Qi-Wei; Pan, Shi-Shi; Qiu, Jian-Ge; Mei, Xiao-Long; Xue, You-Qiu; Qin, Wu-Ming; Zheng, Fei-Yun; Shi, Zhi*; Yan, Xiao-Jian*.Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells.Oxidative Medicine and Cellular Longevity, 2014, 2014: 906804-906804.

[75]Liu, Ju Mei; Pan, Feng; Li, Li; Liu, Qian Rong; Chen, Yong; Xiong, Xin Xin; Cheng, Kejun; Bin Yu, Shang; Shi, Zhi; Yu, Albert Cheung-Hoi; Chen, Xiao Qian*.Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation.Biochemical and Biophysical Research Communications, 2013, 437(1): 87-93.

[76]Zhou, Qi; Mao, Ying-Qing; Jiang, Wei-Dong; Chen, Yun-Ru; Huang, Ren-Yu; Zhou, Xiang-Bing; Wang, Ya-Feng; Shi, Zhi; Wang, Zhong-Sheng; Huang, Ruo-Pan*.Development of IGF Signaling Antibody Arrays for the Identification of Hepatocellular Carcinoma Biomarkers.PLos One, 2012, 7(10): e46851.

[77]Shi, Zhi#; Yang, Wei-Min#; Chen, Li-Pai#; Yang, Dong-Hua; Zhou, Qi; Zhu, Jin; Chen, Jun-Jiang; Huang, Ruo-Chun; Chen, Zhe-Sheng; Huang, Ruo-Pan*.Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production.Breast Cancer Research and Treatment, 2012, 135(3): 737-747.

[78]Wang, Xiu-Wen; Wang, Xiao-Kun; Zhang, Xu; Liang, Yong-Ju; Shi, Zhi; Chen, Li-Ming; Fu, Li-Wu*.FG020326 Sensitized Multidrug Resistant Cancer Cells to Docetaxel-Mediated Apoptosis via Enhancement of Caspases Activation.Molecules, 2012, 17(5): 5442-5458.

[79]Shi, Zhi; Tiwari, Amit K.; Patel, Atish S.; Fu, Li-Wu*; Chen, Zhe-Sheng*。Roles of Sildenafil in Enhancing Drug Sensitivity in Cancer.Cancer Research, 2011, 71(11): 3735-3738. (SCI IF: 8.650) 

[80]Shi Z, Yang WM, Chen LP, Yang DH, Zhou Q, Zhu J, Chen JJ, Huang RC, Chen ZS, Huang RP. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Res Treat. 2012 Oct;135(3):737-47.

[81]Shi, Zhi; Tiwari, Amit K.; Shukla, Suneet; Robey, Robert W.; Singh, Satyakam; Kim, In-Wha; Bates, Susan E.; Peng, Xingxiang; Abraham, Ioana; Ambudkar, Suresh V.; Talele, Tanaji T.; Fu, Li-Wu*; Chen, Zhe-Sheng*.Sildenafil Reverses ABCB1-and ABCG2-Mediated Chemotherapeutic Drug Resistance.Cancer Research, 2011, 71(8): 3029-3041. (SCI IF: 8.650) 

[82]Peng, Xng-Xiang; Shi, Zhi; Tiwari, Amit K.; Damaraju, Vijaya L.; Fu, Liwu; Cass, Carol E.; Ashby, Charles R., Jr.; Kruh, Gary D.; Chen, Zhe-Sheng*.Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells.Oncology Letters, 2011, 2(3): 549-556. 

[83]Abraham, Ioana; Jain, Sandeep; Wu, Chung-Pu; Khanfar, Mohammad A.; Kuang, Yehong; Dai, Chun-Ling; Shi, Zhi; Chen, Xiang; Fu, Liwu; Ambudkar, Suresh V.; El Sayed, Khalid; Chen, Zhe-Sheng*.Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.Biochemical Pharmacology, 2010, 80(10): 1497-1506. 

[84]Dai, Chun-ling; Liang, Yong-ju; Chen, Li-ming; Zhang, Xu; Deng, Wen-jing; Su, Xiao-dong; Shi, Zhi; Wu, Chung-pu; Ashby, Charles R., Jr.; Akiyarna, Shin-ichi; Ambudkar, Suresh V.; Chen, Zhe-sheng*; Fu, Li-wu*.Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.Biochemical Pharmacology, 2009, 78(4): 355-364. 

[85]Zhou, Ying; Hopper-Borge, Elizabeth; Shen, Tong; Huang, Xiao-Cong; Shi, Zhi; Kuang, Ye-Hong; Furukawa, Tatsuhiko; Akiyama, Shin-ichi; Peng, Xing-Xiang; Ashby, Charles R., Jr.; Chen, Xiang; Kruh, Gary D.; Chen, Zhe-Sheng*.Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance.Biochemical Pharmacology, 2009, 77(6): 993-1001.

[86]Shi, Zhi; Tiwari, Amit K.; Shukla, Suneet; Robey, Robert W.; Kim, In-Wha; Parmar, Smitaben; Bates, Susan E.; Si, Qiu-Sheng; Goldblatt, Curtis S.; Abraham, Ioana; Fu, Li-Wu*; Ambudkar, Suresh V.; Chen, Zhe-Sheng*.Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.Biochemical Pharmacology, 2009, 77(5): 781-793.

[87]Shi, Zhi; Parmar, Smitaben; Peng, Xing-Xiang; Shen, Tong; Robey, Robert W.; Bates, Susan E.; Fu, Li-Wu; Shao, Yining; Chen, Yang-Min; Zang, Feiyang; Chen, Zhe-Sheng*。The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.Oncology Reports, 2009, 21(2): 483-489.

[88]Hopper-Borge, Elizabeth; Xu, Xiu; Shen, Tong; Shi, Zhi; Chen, Zhe-Sheng; Kruh, Gary D.*.Human Multidrug Resistance Protein 7 (ABCC10) Is a Resistance Factor for Nucleoside Analogues and Epothilone B.Cancer Research, 2009, 69(1): 178-184.

[89]Peng, Xing-Xiang; Shi, Zhi; Damaraju, Vijaya L.; Huang, Xiao-Cong; Kruh, Gary D.; Wu, Hsiang-Chun; Zhou, Ying; Tiwari, Arnit; Fu, Liwu; Cass, Carol E.; Chen, Zhe-Sheng*.Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine.Leukemia Research, 2008, 32(5): 799-809.

[90]Shi, Zhi; Peng, Xing-Xiang; Kim, In-Wha; Shukla, Suneet; Si, Qiu-Sheng; Robey, Robert W.; Bates, Susan E.; Shen, Tong; Ashby, Charles R., Jr.; Fu, Li-Wu*; Ambudkar, Suresh V.; Chen, Zhe-Sheng*.Erlotinib (Tarceva, OSI-774) antagonizes ATP-bInding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.Cancer Research, 2007, 67(22): 11012-11020.. (SCI IF: 7.543) 

[91]Shi, Zhi; Jain, Sandeep; Kim, In-Wha; Peng, Xing-Xiang; Abraham, Ioana; Youssef, Diaa T. A.; Fu, Li-Wu*; El Sayed, Khalid; Ambudkar, Suresh V.; Chen, Zhe-Sheng*.Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.Cancer Science, 2007, 98(9): 1373-1380.

[92]Jain, Sandeep; Laphookhieo, Surat; Shi, Zhi; Fu, Li-wu; Akiyama, Shin-ichi; Chen, Zhe-Sheng; Youssef, Diaa T. A.; van Soest, Rob W. M.; El Sayed, Khalid A.*.Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids.Journal of Natural Products, 2007, 70(6): 928-931.

[93]Wang, Xiao-hong; Jia, Dian-zeng; Liang, Yong-ju; Yan, Su-li; Ding, Yan; Chen, Li-ming; Shi, Zhi; Zeng, Mu-sheng; Liu, Guang-fei; Fu, Li-wu*.Lgf-YL-9 induces apoptosis in human epidermoid carcinoma KB cells and multidrug resistant KBv200 cells via reactive oxygen species-independent mitochondrial pathway.Cancer Letters, 2007, 249(2): 256-270.

[94]Shi, Zhi; Liang, Yong-Ju; Chen, Zhe-Sheng; Wang, Xiao-Hong; Ding, Yan; Chen, Li-Ming; Fu, Li-Wu*.Overexpression of survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein.Oncology Reports, 2007, 17(4): 969-976.

[95]Shi, Z; Liang, YJ; Chen, ZS; Wang, XW; Wang, XH; Ding, Y; Chen, LM; Yang, XP; Fu, LW*.Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo.Cancer Biology and Therapy, 2006, 5(1): 39-47.

[96]Chen, Li-ming; Liang, Yong-ju; Ruan, Ji-wu; Ding, Yan; Wang, Xiu-wen; Shi, Zhi; Gu, Lian-Quan; Yang, Xiao-ping; Fu, Li-wu*.Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.Journal of Pharmacy and Pharmacology, 2004, 56(8): 1061-1066.

[97]Shi, Z; Fu, LW*.RNAi and its application in tumor study.Progress in Biochemistry and Biophysics, 2004, 31(6): 492-499.

[98]Chen, Li-ming; Wu, Xing-Ping; Ruan, Ji-wu; Liang, Yong-ju; Ding, Yan; Shi, Zhi; Wang, Xiu-wen; Gu, Lian-Quan; Fu, Li-wu*.Screening novel, potent multidrug-resistant modulators from imidazole derivatives.Oncology Research, 2004, 14(7-8): 355-362.

[99]石智.Regulation of cell survival and tumorigenesis by Cables1 complex.廣東省自然科學(xué)基金杰出青年學(xué)術(shù)交流會(huì), China,Guangdong,Dongguan, 2016-12-21 to 2016-12-22.

[100]石智.MiR-194 functions as a tumor suppressor in laryngeal squamous cellcarcinoma by targeting Wee1.2016醫(yī)學(xué)科學(xué)前沿暨第四屆個(gè)體化治療與抗腫瘤藥物研究新趨向研討會(huì), China, 2016-11-05 to 2016-11-07.

[101]Qi-Wei Jiang#; Ke-Jun Cheng#; Xing Wei; Zhi Shi*.Synergistic Anticancer Effects of Triptolide with Celastrol, Two Main Compounds from Thunder God Vine.2015 AACR, United States, 2015-04-18 to 2015-04-22.

[102]Z. Shi; H. Fu*; F.R. Khuri*.The Cables1 protein complex couples survival signaling to cell death machinery.Cell Symposia Hallmarks of Cancer: Asia , China, 2014-11-09 to 2014-11-11.

[103]石智; 程科軍; Haian Fu; Fadlo RKhuri.The Cablesl protein complex couples survival signaling to cell death machinery.中國(guó)細(xì)胞生物學(xué)學(xué)會(huì)（Chinese Society for Cell Biology）.

發(fā)表中文論文

[1]龔麗華, 朱含笑, 周海虹, 石智, 顏笑健. 基于ABCG2的卵巢癌干樣細(xì)胞分選及體外生物學(xué)研究[J]. 浙江醫(yī)學(xué), 2020, 42 (11): 1106-1111+1228.

[2]張文姬, 石智. 小分子酪氨酸激酶抑制劑regorafenib研究進(jìn)展[J]. 腫瘤藥學(xué), 2015, 5 (05): 321-326. 

[3]Survivin shRNA增強(qiáng)人卵巢癌耐藥細(xì)胞OVCAR3對(duì)泰素敏感性的研究 顏笑健; 梁立治; 曾宗淵; 石智; 符立梧 癌癥 2006-04-05

[4]沉默survivin基因介導(dǎo)口腔表皮癌細(xì)胞KB及KBv200凋亡的比較研究 閆琳; 陳偉強(qiáng); 梁永鉅; 戴春嶺; 王曉紅; 石智; 陳黎明; 符立梧 癌癥 2006-08-05

[5]FG020326通過增加泰素帝介導(dǎo)caspase-8和3激活的敏感性克服多藥耐藥細(xì)胞MCF-7/ADR的凋亡抗性 王秀文; 丁巖; 梁永鉅; 陳黎明; 石智; 楊小平; 古練權(quán); 符立梧 癌癥 2004-12-30

所獲榮譽(yù)： 

1、獲科學(xué)中國(guó)人(2013)年度人物。

2、入選廣東省特支計(jì)劃科技創(chuàng)新青年拔尖人才 。

3、廣東省千百十工程校級(jí)培養(yǎng)計(jì)劃。

4、暨南大學(xué)杰出青年學(xué)者支持計(jì)劃。

所獲獎(jiǎng)勵(lì)： 

獲得中國(guó)抗癌協(xié)會(huì)科技獎(jiǎng)一等獎(jiǎng)、廣東省科學(xué)技術(shù)獎(jiǎng)一等獎(jiǎng)和中國(guó)藥理學(xué)會(huì)施維雅青年藥理學(xué)家獎(jiǎng)等獎(jiǎng)項(xiàng)12項(xiàng)。

[1]常用畬藥全產(chǎn)業(yè)鏈質(zhì)量提升關(guān)鍵技術(shù)創(chuàng)新與應(yīng)用，

程科軍; 呂群丹; 金葉; 石智; 李西文; 毛菊華; 陳軍華; 王奎武; 王偉影; 方潔; 童應(yīng)鵬; 吉慶勇; 潘俊杰; 廖北云; 胡理濱

中國(guó)民族醫(yī)藥協(xié)會(huì), 中國(guó)民族醫(yī)藥協(xié)會(huì)科學(xué)技術(shù)獎(jiǎng), 二等獎(jiǎng), 2020.

[2]畬藥質(zhì)量控制關(guān)鍵技術(shù)研究及應(yīng)用

程科軍; 石智; 呂群丹; 王奎武; 潘俊杰; 方潔; 吳劍鋒

浙江省科技廳, 浙江省科技進(jìn)步獎(jiǎng), 三等獎(jiǎng), 2020.

[3]畬藥質(zhì)量控制關(guān)鍵技術(shù)研究及應(yīng)用

程科軍; 石智; 王奎武; 呂群丹; 黃剛; 楊國(guó)勛; 潘俊杰; 金葉; 陳正道; 方潔; 王偉影; 程文亮; 毛菊華; 吉慶勇; 胡理濱

中國(guó)民族醫(yī)藥協(xié)會(huì), 其它, 一等獎(jiǎng), 2019.

[4]天然產(chǎn)物蓽茇酰胺治療腫瘤的機(jī)制及其應(yīng)用

潘峰; 陳曉釬; 劉迪; 石智; 陳勇; 劉菊梅; 熊昕昕; 邱辛瑤; 劉倩蓉; 陳若喬; 余上斌; 謝小強(qiáng); 胡殿興; 劉鋒; 李春陽

湖北省科技廳, 科技進(jìn)步, 省部二等獎(jiǎng), 2019.

[5]中國(guó)藥理學(xué)會(huì)施維雅青年藥理學(xué)家獎(jiǎng)

石智

中國(guó)藥理學(xué)會(huì), 其它, 施維雅青年藥理學(xué)家獎(jiǎng), 2018.

[6]特色野生藥材保護(hù)利用研究

程科軍; 石智; 徐金標(biāo); 吉慶勇; 俞培忠; 吳華芬; 諸葛華; 胡金鋒; 程文亮

浙江省科技廳, 浙江省科技進(jìn)步獎(jiǎng), 其它, 2017.

[7]克服ABC藥物轉(zhuǎn)運(yùn)泵介導(dǎo)的腫瘤多藥抗藥性的研究

符立梧; 梁永鉅; 石智; 戴春嶺; 閆燕艷

廣東省科技廳, 2012年度廣東省科學(xué)技術(shù)獎(jiǎng), 一等獎(jiǎng), 2013.

[8]克服ABC藥物轉(zhuǎn)運(yùn)泵介導(dǎo)的腫瘤多藥抗藥性的研究

符立梧; 梁永鉅; 石智; 戴春嶺; 閆燕艷; 陳黎明

中華醫(yī)學(xué)會(huì), 2012年度中華醫(yī)學(xué)科技獎(jiǎng), 三等獎(jiǎng), 2013.

[9]克服ABC藥物轉(zhuǎn)運(yùn)泵介導(dǎo)的腫瘤多藥抗藥性的研究

符立梧; 梁永鉅; 石智; 戴春嶺; 閆燕艷

中國(guó)抗癌協(xié)會(huì), 2011年度中國(guó)抗癌協(xié)會(huì)科技獎(jiǎng), 一等獎(jiǎng), 2012.

[10]克服ABC藥物轉(zhuǎn)運(yùn)泵介導(dǎo)的腫瘤多藥抗藥性的研究

符立梧; 梁永鉅; 石智; 戴春嶺; 閆燕艷; 潘啟超

教育部, 2011年度高等學(xué)�？茖W(xué)研究?jī)?yōu)秀成果獎(jiǎng)(科學(xué)技術(shù))自然科學(xué)獎(jiǎng), 二等獎(jiǎng), 2011.

[11]多種策略逆轉(zhuǎn)P-糖蛋白和乳腺癌耐藥相關(guān)蛋白介導(dǎo)的腫瘤多藥耐藥

石智

廣東省教育廳、廣東省學(xué)位委員會(huì), 2009年度廣東省優(yōu)秀學(xué)位論文, 優(yōu)秀博士論文, 2010.